ClinicalTrials.gg
CompletedNCT01077739Updated Dec 15, 2014Results posted

A Study of Avastin (Bevacizumab) With XELOX or FOLFOX in Patients With Metastatic Colorectal Cancer and Disease Progression Under First-line FOLFIRI and Avastin

A Phase 2 interventional study of fluorouracil (5FU) and leucovorin in Colorectal Cancer, sponsored by Hoffmann-La Roche. Completed at 28 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-12-15.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 159 studies testing fluorouracil in Colorectal Neoplasms — 15 open to participants now, 19 under way, 4 of them phase 3. Fluorouracil · Colorectal Neoplasms.

Enrollment
60th of 132
75 · median 66
Started
2009
with 4 others
Phase 2
79 of 159
6 open now
Registered
103rd of 159
by date

Among the 159 studies testing fluorouracil in Colorectal Neoplasms, this one is the 60th largest by enrollment of the 132 interventional ones that give a count, is one of 5 that started in 2009, is one of 79 in phase 2, and was the 103rd registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

15 of the 159 studies testing fluorouracil in Colorectal Neoplasms are open now, in 7 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About fluorouracil

Fluorouracil: first FDA approval 1962 (FLUOROURACIL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 159 studies testing fluorouracil in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This open-label single arm study will evaluate the efficacy and safety of Avastin added to XELOX or FOLFOX in patients with metastatic colorectal cancer and disease progression on 1st line therapy with FOLFIRI plus Avastin. Patients will receive either Avastin (7.5mg/kg iv infusion every 3 weeks) and standard XELOX (Xeloda [capecitabine] plus oxaliplatin) chemotherapy or Avastin (5 mg/kg iv infusion every 2 weeks) and standard FOLFOX (5-FU and leucovorin plus oxaliplatin) chemotherapy. The anticipated time on study treatment is until disease progression, and the target sample size is 100 individuals.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients >/=18 years of age
  • colorectal cancer
  • at least 1 according to v. 1.1
  • patients with disease progression with prior FOLFIRI + Avastin therapy who are not candidates for primary metastasectomy
  • disease progression \</= 8 weeks after last dose of Avastin
  • \</=2
  • No more than 8 weeks between treatment with FOLFIRI + Avastin and 2nd-line treatment with XELOX or FOLFOX + Avastin

Exclusion criteria

Exclusion Criteria:

  • disease progression > 8 weeks after last Avastin administration
  • cardiovascular disease
  • CNS disease except for treated
  • history of other within 2 years prior to start of study treatment (with the exception of curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix)
  • major surgery, open , or significant traumatic injury within 28 days prior to start of study treatment
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (actual)

Study arms

  • Experimental
    Avastin (bevacizumab) + standard of care

    Drug: fluorouracil (5FU) · Drug: leucovorin · Drug: bevacizumab [Avastin] · Drug: capecitabine [Xeloda] · Drug: oxaliplatin

Interventions

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression

    PFS from the start of treatment beyond progression was defined as the interval between the start of beyond-progression therapy and the date at which disease progression was documented. Progression of disease was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 and abdominal/pelvic computerized tomography (CT) or magnetic resonance imaging (MRI) scanning as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The same method of assessment and the same technique were to be used to evaluate each lesion throughout the entire study. If more than one method was used, data from the most accurate method according to RECIST were recorded. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: Baseline, every 9 weeks until disease progression, at end of treatment or withdrawal, for up to 24 months

Secondary outcomes

  1. PFS From the Start of First-Line Therapy

    PFS from the start of first-line therapy was defined as the interval between the start of first-line therapy and the date at which second disease progression (after the start of beyond progression therapy) was documented. Progression of disease was evaluated using RECIST version 1.1 and abdominal/pelvic CT or MRI scanning. The same method of assessment and the same technique were to be used to evaluate each lesion throughout the entire study. If more than one method was used, data from the most accurate method according to RECIST were recorded. Median PFS was estimated using the Kaplan-Meier method.

    Time frame: Baseline, every 9 weeks until disease progression, at end of treatment or withdrawal, for up to 24 months

  2. Percentage of Participants With an Overall Response of Complete Response (CR) or Partial Response (PR)

    Percentage of participants with an overall response of CR or PR according to RECIST criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\]10 millimeters \[mm\]). No new lesions. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

    Time frame: Baseline, every 9 weeks until disease progression, at end of treatment or withdrawal, for up to 24 months

  3. Geometric Mean Values of Pro-Angiogenic Cytokine Concentrations at Baseline and Prior to Progression

    Pro-angiogenic cytokine concentrations of placental growth factor (PlGF), basic fibroblast growth factor (bFGF), and hepatocyte growth factor (HGF) in participant sera were measured and reported in units of picograms/milliliter (pg/mL). The geometric mean was calculated as exp10 (mean of log10 transformed concentration) and the standard deviation (SD) is SD of log10 transformed concentration.

    Time frame: Baseline, every 9 weeks until disease progression, at final visit or at withdrawal, for up to 24 months

07

Results

Posted Aug 7, 2014

Participant flow

Participant flow — Overall Study
MilestoneBevacizumab + Oxaliplatin + CapecitabineBevacizumab + 5-fluorouracil/Oxaliplatin/Leucovorin (FOLFOX)
Started2550
Completed2040
Not completed510
Withdrew: Premature withdrawal13
Withdrew: Withdrawal by subject10
Withdrew: Death03
Withdrew: Unacceptable toxicity12
Withdrew: Other22

Outcome measures

PrimaryProgression-Free Survival (PFS) From the Start of Treatment Beyond Progression

PFS from the start of treatment beyond progression was defined as the interval between the start of beyond-progression therapy and the date at which disease progression was documented. Progression of disease was evaluated using Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 and abdominal/pelvic computerized tomography (CT) or magnetic resonance imaging (MRI) scanning as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions. The same method of assessment and the same technique were to be used to evaluate each lesion throughout the entire study. If more than one method was used, data from the most accurate method according to RECIST were recorded. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
Baseline, every 9 weeks until disease progression, at end of treatment or withdrawal, for up to 24 months
Reported as:
Median · months
Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression
monthsBevacizumab + Oxaliplatin + CapecitabineBevacizumab + FOLFOX
Progression-Free Survival (PFS) From the Start of Treatment Beyond Progression6.3 (4.1 to 7.6)5.1 (3.8 to 6.0)
SecondaryPFS From the Start of First-Line Therapy

PFS from the start of first-line therapy was defined as the interval between the start of first-line therapy and the date at which second disease progression (after the start of beyond progression therapy) was documented. Progression of disease was evaluated using RECIST version 1.1 and abdominal/pelvic CT or MRI scanning. The same method of assessment and the same technique were to be used to evaluate each lesion throughout the entire study. If more than one method was used, data from the most accurate method according to RECIST were recorded. Median PFS was estimated using the Kaplan-Meier method.

Time frame:
Baseline, every 9 weeks until disease progression, at end of treatment or withdrawal, for up to 24 months
Reported as:
Median · months
PFS From the Start of First-Line Therapy
monthsBevacizumab + Oxaliplatin + CapecitabineBevacizumab + FOLFOX
PFS From the Start of First-Line Therapy17.8 (14.1 to 19.4)18.0 (15.0 to 19.9)
SecondaryPercentage of Participants With an Overall Response of Complete Response (CR) or Partial Response (PR)

Percentage of participants with an overall response of CR or PR according to RECIST criteria. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must have decreased to normal (short axis less than \[\<\]10 millimeters \[mm\]). No new lesions. PR was defined as greater than or equal to (≥)30 percent (%) decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.

Time frame:
Baseline, every 9 weeks until disease progression, at end of treatment or withdrawal, for up to 24 months
Reported as:
Number · percentage of participants
Percentage of Participants With an Overall Response of Complete Response (CR) or Partial Response (PR)
percentage of participantsBevacizumab + Oxaliplatin + CapecitabineBevacizumab + FOLFOX
Percentage of Participants With an Overall Response of Complete Response (CR) or Partial Response (PR)27.36.4
SecondaryGeometric Mean Values of Pro-Angiogenic Cytokine Concentrations at Baseline and Prior to Progression

Pro-angiogenic cytokine concentrations of placental growth factor (PlGF), basic fibroblast growth factor (bFGF), and hepatocyte growth factor (HGF) in participant sera were measured and reported in units of picograms/milliliter (pg/mL). The geometric mean was calculated as exp10 (mean of log10 transformed concentration) and the standard deviation (SD) is SD of log10 transformed concentration.

Time frame:
Baseline, every 9 weeks until disease progression, at final visit or at withdrawal, for up to 24 months
Reported as:
Geometric mean · pg/mL
Geometric Mean Values of Pro-Angiogenic Cytokine Concentrations at Baseline and Prior to Progression
pg/mLBevacizumab + Oxaliplatin + CapecitabineBevacizumab + FOLFOX
Baseline bFGF (n=13,23)6.8 ± 0.76.1 ± 0.6
bFGF, Prior to progression levels (n=12,18)3.6 ± 0.94.2 ± 0.7
Baseline HGF (n=13,23)133.0 ± 0.3186.0 ± 0.4
HGF, Prior to progression levels (n=12,18)187.3 ± 0.4230.3 ± 0.4
Baseline PIGF (n=13,23)29.8 ± 0.126.3 ± 0.2
PIGF, Prior to progression levels (n=12,18)34.7 ± 0.137.1 ± 0.2

Adverse events

Collected over Adverse events (AEs) were reported from Day 1 until 28 days after last dose of study medication for up to 24 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bevacizumab + Oxaliplatin + Capecitabine—12/25 (48%)24/25 (96%)
Bevacizumab + FOLFOX—18/50 (36%)49/50 (98%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventBevacizumab + Oxaliplatin + CapecitabineBevacizumab + FOLFOX
Drug toxicityInjury, poisoning and procedural complications2/250/50
DehydrationMetabolism and nutrition disorders2/251/50
General physical health deteriorationGeneral disorders0/253/50
Abdominal painGastrointestinal disorders1/251/50
Abdominal pain upperGastrointestinal disorders1/251/50
Anal fistulaGastrointestinal disorders1/250/50
DiarrhoeaGastrointestinal disorders1/252/50
EnteritisGastrointestinal disorders1/250/50
VomitingGastrointestinal disorders1/251/50
AstheniaGeneral disorders1/250/50
Most frequent other events
Showing 10 of 158
Most frequent other events
EventBevacizumab + Oxaliplatin + CapecitabineBevacizumab + FOLFOX
DiarrhoeaGastrointestinal disorders14/2521/50
FatigueGeneral disorders9/2522/50
NauseaGastrointestinal disorders10/2516/50
Abdominal painGastrointestinal disorders9/2513/50
Decreased appetiteMetabolism and nutrition disorders9/2512/50
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders8/252/50
Neuropathy peripheralNervous system disorders7/259/50
HypertensionVascular disorders3/2513/50
VomitingGastrointestinal disorders6/255/50
ParaesthesiaNervous system disorders6/2510/50

Baseline characteristics

Intent-to-treat (ITT) population: all enrolled participants who received at least 1 dose of the investigational and non-investigational products.

Age, Continuous
Age, Continuous(years)Bevacizumab + Oxaliplatin + CapecitabineBevacizumab + FOLFOXTotal
Mean59.6 ± 8.964.9 ± 8.763.1 ± 9.0
Sex: Female, Male
Sex: Female, Male(Participants)Bevacizumab + Oxaliplatin + CapecitabineBevacizumab + FOLFOXTotal
Female82129
Male172946
08

Study locations

28 sites
  • Aalst, 9300, Belgium
  • Arlon, 6700, Belgium
  • Assebroek, 8310, Belgium
  • AYE, 6900, Belgium
  • Bonheiden, 2820, Belgium
  • Brasschaat, 2930, Belgium
  • Brugge, 8000, Belgium
  • Bruxelles, 1020, Belgium
  • Bruxelles, 1180, Belgium
  • Bruxelles, 1200, Belgium
  • Charleroi, 6000, Belgium
  • Dendermonde, 9200, Belgium
  • Edegem, 2650, Belgium
  • Genk, 3600, Belgium
  • Gent, 9000, Belgium
  • Hasselt, 3500, Belgium
  • Kortrijk, 8500, Belgium
  • Mechelen, 2800, Belgium
  • Merksem, 2170, Belgium
  • Mont-godinne, 5530, Belgium
  • Montigny-le-Tilleul, 6110, Belgium
  • Namur, 5000, Belgium
  • Oostende, 8400, Belgium
  • Sint-Niklaas, 9100, Belgium
  • Tournai, 7500, Belgium
  • Turnhout, 2300, Belgium
  • Verviers, 4800, Belgium
  • Wilrijk, 2610, Belgium
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Jan 2012 and a completion of Jan 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2014, 2 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2010
First posted
Mar 1, 2010
Start
Jul 2009
Primary completionActual
Jan 2012
CompletionActual
Jan 2012
Results first posted
Aug 7, 2014
Last update
Dec 15, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01077739
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Mar 1, 2010
Start date
Jul 2009
Primary completion
Jan 2012
Completion
Jan 2012
Results posted
Aug 7, 2014
Last update
Dec 15, 2014

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluorouracil · Leucovorin · Bevacizumab · Capecitabine · Oxaliplatin

Start the discussion